What do the new ESC Guidelines for the treatment of heart failure bring to internists?

Czech version

Authors: Jindřich Špinar; Lenka Špinarová; Jiří Vítovec
Authors‘ workplace: I. interní kardioangiologická klinika FN USA a LF MU, Brno
Published in: Vnitř Lék 2022; 68(2): 104-110
Category: Review Articles

Overview

Chronic heart failure is in european countries in 0,4–2,0% population with an increase with age. The improved care of acute cases enables to decrease the number of patients with chronic heart failure.The disease has a bad prognosis, the diagnosis therapy are demanding. European guidelines for diagnosis and treatment heart failure stress, that patients should have all 4 drugs with class 1 reccomendation (ACE‑ I/ARNI, betablockers, MRA and SGLT2) in reccomended doses. These drugs will be given step by step with dose titration.

Keywords:

diagnosis – treatment – chronic heart failure

Sources

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021;00:1-128. doi: 101093/eurheartj/ehab 368.

Labels

Diabetology Endocrinology Internal medicine

Editorial

Prediabetes

ADA Standards of Medical Care in Diabetes 2022 – what’s new?

Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice

The position of SGLT2 inhibitors in current medical practice – update 2022

Anticoagulation in cancer patients; new recommendations based on randomized clinical trials

Colorectal cancer in patients with diabetes – epidemiology, pathophysiology and applications for clinical practice

Any expectations from the more powerful dulaglutide?

Pituitary incidentaloma

Pharmacological possibilities of vitamin C in oncology

Article was published in

Internal Medicine

2022 Issue 2